Prophylaxis and treatment of venous thromboembolism in cancer patients: a review.
Thromboprophylaxis is underused in patients with cancer, despite the fact that malignancy is a serious risk factor for venous thromboembolism in this population. Major medical guidelines, including those published recently by the American College of Chest Physicians, the American Society of Clinical Oncology, and the National Comprehensive Cancer Network, recommend routine thromboprophylaxis for patients with cancer under certain situations. This review describes current recommendations for primary and secondary prophylaxis in patients with cancer.
Ansell
Jack E
JE
Department of Medicine, Lenox Hill Hospital, New York, NY 10075, USA. jansell@lenoxhill.net
D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000150:complications* / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D017410:Practice Guidelines as Topic; D011322:Primary Prevention / Q000379:methods; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome; D054556:Venous Thromboembolism / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality / Q000517:prevention & control*
D000925:Anticoagulants